Skip to content

AIM ImmunoTech Ampligen shows encouraging prophylactic effect v. Covid

August 27, 2020

Results from a 3D-mucociliary tissue culture showed AIM ImmunoTech’s (AIM +12.3%) Ampligen, a dsRNA TLR3 agonist, decreased SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels.

“We are pleased with these results, as they establish Ampligen’s bio-activity against SARS-CoV-2 as well as support our decision to test Ampligen in humans as an intranasal prophylaxis and early-onset therapy against COVID-19,” said its CEO Thomas Equels

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: